ArticleMolecular biology reports2011
DLC-1 as a modulator of proliferation, apoptosis and migration in Burkitt's lymphoma cells.
Article in Molecular biology reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- EZB-type diffuse large B-cell lymphoma cell lines have superior migration capabilities compared to MCD-type.British journal of haematology · 2024Article
- Review
- Deleted in liver cancer 1 suppresses the growth of prostate cancer cells through inhibiting Rho-associated protein kinase pathway.Asian journal of urology · 2023Article
- ARHGAP24 inhibits cell proliferation and cell cycle progression and induces apoptosis of lung cancer via a STAT6-WWP2-p27 axis.Carcinogenesis · 2020Article
- Burkitt lymphoma-associated network construction and important network motif analysis.Oncology letters · 2018Article
- Deleted in liver cancer 1 expression and localization in hepatocellular carcinoma tissue sections.Oncology letters · 2014Article
- Uncovering the rare variants of DLC1 isoform 1 and their functional effects in a Chinese sporadic congenital heart disease cohort.PloS one · 2014Article
- DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- DLC1 as a regulator of proliferation, invasion, cell cycle, and apoptosis in cutaneous squamous cell carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- Effect of small interfering RNA transfection on FAK and DLC1 mRNA expression in OVCAR-3.Molecular biology reports · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deleted in liver cancer-1(DLC-1) gene expression is frequently down-regulated or deleted in many types of human cancer. To evaluate whether DLC-1 could be a therapeutic target for non-Hodgkin lymphoma (NHL), we examined the expressions of DLC-1 in Burkitt's lymphoma (BL) cell lines and tested the effects of DLC-1 on cellular growth and migration in BL cells. DLC-1 expression was not detectable in two human BL cell lines, Raji and Daudi, by reverse transcription-PCR. The transfer of DLC-1 into Raji and Daudi cell lines caused a significant inhibition in cell proliferation. This inhibitory effect on cell proliferation in BL cell lines was accompanied by induction of apoptosis. Furthermore, restoration of DLC-1 expression in BL cells had a significant inhibitory effect on migration. Our findings suggest that DLC-1 may play an important role in lymphoma by acting as a bona fide new tumor suppressor gene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.